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Oxidative stress has been implicated in the pathogenesis of asthma. We aimed at investigating the biomarkers of oxidative
stress, inflammation, and tissue damage in patients with asthma in acute exacerbation and remission. We recruited 18 asthmatics
admitted to hospital with acute exacerbation and 18 healthy nonsmoking controls matched for age. We evaluated plasma levels
of 8-isoprostane, C-reactive protein (CRP) and total matrix metalloproteinase- (MMP-) 9 by ELISA, and MMP-9 activity by
zymographic analysis. Plasma levels of 8-isoprostane and CRP were significantly elevated in acute exacerbation and decreased
in remission but remained significantly higher compared to healthy controls. The activities of pro-MMP-9 were also significantly
higher in acute exacerbation and decreased in remission but remained significantly higher compared to healthy controls in parallel
to plasma levels of total MMP-9. These data suggest that overproduction of MMP-9 along with highly elevated levels of oxidative
stress and inflammation is implicated in asthma exacerbation and that measurements of these biomarkers can be a valid index in
its management.
1. Introduction
Asthma is a chronic inflammatory airway disease that affects
children and adults of all ages [1]. Chronic inflammation,
which involves recruitment and activation of inflammatory
cells, has been increasingly recognized as a mechanism lead-
ing to oxidative stress in asthma [2]. According to Wark and
Gibson [3], the patterns of airway inflammation are differ-
ent for different triggering factors, while the exaggerated
response of asthmatic airways is still not completely well
known. 8-Isoprostane is considered a marker of oxidative
stress specific for lipid peroxidation, which is a stablemetabo-
lite of arachidonic acid, synthesized in vivo, and biologically
active [4]. Previous studies found higher 8-isoprostane levels
in the plasma, exhaled breath condensate (EBC), and induced
sputum in asthmatic patients [5–7]. In the few studies carried
out on patients in acute exacerbation of asthma, changes
in oxidative stress have been reported, including increased
plasma thiobarbituric acid reactive substances (TBARS),
exhaled pentane levels, and exhaled breath 8-isoprostane in
acute exacerbation versus stable asthma [8–10].
C-reactive protein (CRP), an acute-phase protein, is a
highly sensitive systemic marker of inflammation, infection,
and tissue damage [11]. Beside airway inflammation, several
studies have indicated a positive relationship between asthma
and increased CRP levels [12–17]. Recently, Fujita et al.
found that serum CRP levels might be related to asthma
exacerbations [18].
Airway remodeling, an excess of extracellular matrix
(ECM) deposition in the airway wall, which leads to subep-
ithelial collagen deposition, is awell-known feature of asthma.
Thematrixmetalloproteinases (MMPs) belong to a large fam-
ily of zinc- and calcium-dependent endopeptidases with
distinct substrate specificities that degrade all types of ECM
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components. The MMPs play an important role in physio-
logical and pathological processes, including ECM turnover,
tissue degradation and repair, cell migration, and inflamma-
tion. Of the MMP family, MMP-9 is the major proteinase
that induces airway remodeling in asthma [19]. MMP-9
is the most prominent MMPs found in bronchoalveolar
lavage fluid, in sputum, and in serum [20–23]. It has been
reported that eosinophils are amajor cellular source ofMMP-
9 in bronchial tissue in asthmatic patients [24]. The levels
of MMP-9 in sputum or in plasma have been related to
the severity of asthma, with more severe asthmatics having
higher levels than those with mild asthma [25, 26].
As acute exacerbation of asthma might contribute to
airway remodeling by changing the levels of biomarkers for
oxidative stress and inflammation, we therefore determined
plasma levels of 8-isoprostane (biomarker of oxidative stress),
CRP (biomarker of systemic inflammation), and total MMP-
9 as well as MMP-9 activity in patients with asthma in acute
exacerbation and in remission.
2. Materials and Methods
2.1. Study Subjects. Asthma is defined as those with a history
of cough or wheeze and the presence of reversible airflow
obstruction [27]. Eighteen patients with asthma admit-
ted into two local hospitals with acute exacerbation were
recruited by a research nurse within the first 24 hours of their
admission. They all had received systemic corticosteroids
within the first 24 hours of admission. A venous blood sample
of 10mL was collected before or shortly after the adminis-
tration of systemic corticosteroids. A detailed questionnaire
about their demographic characteristics was completed by
the research nurse, and spirometry was carried out according
to the American Thoracic Society recommendation [28] at
the time. Another blood sample was taken, and spirometry
was done again when the patients were in remission usually
at 4 to 6weeks after discharge fromhospital. Eighteen patients
were recruited from two local hospitals. In addition, 18
healthy nonsmoking subjects without respiratory symptoms
were also recruited locally from the work place to serve as
age-matched controls. All subjects had allergy skin prick
test to one or more common allergens during the follow-up
visit. A positive skin test reaction was defined as one with a
wheal diameter equal or greater than 3mm in comparison to
the histamine positive and the saline negative control at 15
minutes after testing.
Written informed consent was obtained from each par-
ticipant of the study. This study was approved by the Ethics
Committee of HKU/HA HKW IRB (UW 06-348).
2.2. Blood Samples. Fresh venous blood samples were col-
lected into evacuated tubes containing lithium heparin and
centrifuged at 1600×g for 10 minutes under 4∘C. The plasma
and buffy coat were separated.
2.3. Measurement of Plasma 8-Isoprostane, C-Reactive Protein
(CRP), and Matrix Metalloprotease- (MMP-) 9. Levels of
8-isoprostane (Oxis Research, TX, USA), CRP (Diagnostic
System Laboratories Inc., TX, USA), and total MMP-9 (R &
D Systems) in plasma were measured using as commercially
available enzyme-linked immunosorbent assay (ELISA) kits
according to the manufacturer’s instruction. All measure-
ments were performed in duplicate andmeasured in adjacent
wells to minimize assay variability.
2.4. Evaluation of Plasma Gelatinases (MMP-2 and MMP-
9) Activities. MMP-2 and MMP-9 activities were analysed
by zymography using 1mg/mL gelatine as substrate. This
method allows the determination of various types of MMPs
on the basis of their molecular weight and allows the
determination of their state of activation (latent and/or active
forms).
Aliquots of plasma were subjected to electrophoresis on
sodium dodecyl sulphate- (SDS-) polyacrylamide gel under
nonreducing condition. After electrophoresis, gels were
washed twice in 50mM Tris-HCl (pH 7.6), 5mM CaCl
2
, and
2.5% Triton X-100 for 1 h, rinsed abundantly with water, and
then incubated in 50mMTris-HCl (pH 7.6), 5mMCaCl
2
, 1%
Triton X-100, and 0.02% NaN
3
at 37∘C for 18 h. The reaction
was stopped by staining the gels with 0.1% Coomassie
Brilliant Blue R250 and then destained in a solution of 10%
acetic acid and 30% methanol. The molecular weights of
gelatinolytic bandswere estimated using recombinant protein
molecular weight markers (10,000–225,000Da) (Amersham
Biosciences). The gelatinolytic activity was visualized as clear
bands against a blue background, and the band intensity
was quantified with a densitometric analyzer with GeneTools
(Syngene, Frederick, MD, USA).
2.5. Statistical Analysis. Variables were presented as mean
± standard deviation (SD) or median (interquartile range).
Wilcoxon’s matched-signed ranks test was used to conduct
pairwise comparisons of the biomarkers between asthmatic
groups at acute asthma attack and during remission. Mann-
Whitney𝑈-tests were used to compare the difference between
asthmatic and healthy control groups. Correlations between
plasma biomarker levels and other lung function parameters
were determined by Spearman’s rank correlation coefficient.
SPSS forWindows version 14.0 (SPSS, Chicago, IL, USA) was
used for statistical analyses where appropriate. A 𝑃 value <
0.05 was considered statistically significant in all analyses.
3. Results
Eighteen atopic, nonsmoking patients with asthma, 5 males
and 13 females, aged 18 to 61 yearswere included for this study.
In addition, 18 healthy nonsmoking age-matched controls
were recruited consisting of 6 males and 12 females, aged
18–65 years; of these, 9 were atopic and 9 nonatopic. The
lung function parameters (FVC (% predicted) and FEV
1
(% predicted)) but not FEV
1
/FVC ratio (%) significantly
improved during remission compared with those during
acute exacerbation and were significantly lower than healthy
controls (Table 1).
Plasma levels of 8-isoprostane, CRP, and total MMP-9
were significantly higher in patients in acute exacerbation
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Table 1: Lung function parameters of asthmatics and healthy controls.
Asthma Control
Exacerbation Remission
FVC (% predicted) 79.0 ± 24.3∗,† 99.0 ± 22.9 107.4 ± 14.7
FEV1 (% predicted) 62.6 ± 31.4
∗,†
84.8 ± 26.1
‡
108.4 ± 14.6
FEV1/FVC ratio (% predicted) 74.7 ± 19.1
†
84.4 ± 11.3
‡
101.2 ± 5.4
∗P < 0.05 for comparison between acute exacerbation and remission in asthma.
†P < 0.001 for comparison between asthmatics during acute exacerbation and healthy controls.
‡P < 0.01 for comparison between asthmatics during remission and healthy controls.
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Figure 1: Box plots of plasma 8-isoprostane levels in asthmatic
patients (𝑛 = 18) during acute exacerbation and remission and age-
matched healthy controls (𝑛 = 18). The horizontal bars represent
median values. ∗∗∗𝑃 < 0.001 differences between acute exacerbation
or remission and healthy controls; ##𝑃 < 0.01 differences between
acute exacerbation and remission by nonparametricWilcoxon’s rank
sum test.
than those in remission or in healthy controls (𝑃 < 0.01; Fig-
ures 1, 2, and 3). Zymographic analysis showed the presence
of the 72-KDa pro-MMP-2 and 92-KDa pro-MMP-9 bands
(Figure 4(a)). We found a significant increase in activity of
MMP-9 but not MMP-2 in the plasma of patients in acute
exacerbation than those in remission or in healthy controls
(𝑃 < 0.01; Figure 4(b)).
We correlated plasma levels of each of the biomarkers
with lung function parameters (FEV
1
(% predicted), FVC
(% predicted), and ratio of FEV
1
/FVC (%)) in acute exacer-
bation and in remission.There were a significant positive cor-
relation between plasma 8-isoprostane levels and FEV
1
/FVC
(𝑟 = 0.746, 𝑃 < 0.001) and a significant negative correlation
between plasma total MMP-9 levels and FEV
1
/FVC (𝑟 =
−0.495, 𝑃 < 0.05) in acute exacerbation but not in remission.
No correlation was found between plasma CRP levels and
any of the lung function parameters. A significant negative
correlation also existed between the plasma levels of 8-iso-
prostane and total MMP-9 (𝑟 = −0.524, 𝑃 < 0.05) in acute
exacerbation but not in remission.
4. Discussion
In this study we found that plasma levels of 8-isopros-
tane, CRP, total MMP-9, and 92-KDa MMP-9 activity were
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Figure 2: Box plots of plasma CRP levels in asthmatic patients
(𝑛 = 18) during acute exacerbation and remission and age-matched
healthy controls (𝑛 = 18). The horizontal bars represent median
values. ∗∗∗𝑃 < 0.001 differences between acute exacerbation or
remission andhealthy controls; ##𝑃 < 0.01differences between acute
exacerbation and remission by nonparametric Wilcoxon’s rank sum
test.
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Figure 3: Box plots of plasma total (active and pro) MMP-9
levels in asthmatic patients (𝑛 = 18) during acute exacerbation
and remission and age-matched healthy controls (𝑛 = 18). The
horizontal bars represent median values. ∗∗𝑃 < 0.01 differences
between acute exacerbation or remission and healthy controls;
##
𝑃 < 0.01 differences between acute exacerbation and remission
by nonparametric Wilcoxon’s rank sum test.
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Figure 4: Analysis of plasma by gelatin zymography showing circulating gelatinolytic activities in healthy controls (HC) and their changes
during an asthma acute exacerbation (AE) and subsequent remission (R). (a) A representative zymographic analysis of plasma samples from
3 healthy controls and 2 asthmatic patients suffering acute exacerbation and during remission. Twomajor bands are visible, corresponding to
pro-MMP-2 (72KDa) and pro-MMP-9 (92KDa). Pro-MMP-9 activity is higher during an asthma acute exacerbation than during remission,
whereas pro-MMP-2 activity remains constant. (b) Box plots of densitometric analyses of the zymographs as pro-MMP-9 activities. The
horizontal bars represent median values. ∗∗∗𝑃 < 0.001 differences between acute exacerbation or remission and healthy controls; ##𝑃 < 0.01
differences between acute exacerbation and remission by nonparametric Wilcoxon’s rank sum test.
significantly increased in patients with asthma in acute exac-
erbation and decreased in remission but remained elevated
compared with healthy controls. These findings suggest that
there are a sustained systemic oxidative stress and inflam-
mation and airway remodeling during recovery from acute
exacerbation of asthma.
There is increasing evidence that asthma is a disease
associated with increased oxidative stress [29]. In support,
we found persistent elevated levels of 8-isoprostane during
remission compared to healthy controls. One explanation
could be its resistance to corticosteroids as demonstrated
by Montuschi et al. [5] who reported that patients with
severe asthma treated with oral prednisolone had higher 8-
isoprostane levels in their exhaled breath condensates than
patients with mild and moderate asthma.
CRP is one of themost characteristic surrogatemarkers of
systemic inflammation. Our results confirmed the presence
of low-grade systemic inflammation in asthma as shown
previously [12–17]. In agreement with previous reports [18,
29], we found significantly higher plasma CRP levels at
acute exacerbation and remained elevated during remission
compared with healthy controls, reflecting chronic systemic
inflammation in asthma.
The findings of higher levels of MMP-9 levels in the pro-
form (92KDa) without changes in MMP-2 level in asthmatic
patients at acute exacerbation than during remission in our
study are also compatiblewith other investigators [26, 30] and
suggest the involvement of MMP-9 in airway inflammation
and remodeling. Inhaled steroids treatment has been found
to decrease MMP-9 activity in some [20, 31, 32], but not in
all, reports [25].
We found that the ratio of FEV
1
/FVC (%) was positively
correlated with plasma 8-isoprostane levels while negatively
correlating with total MMP-9, but there were no correlations
between FEV
1
or FVC (% predicted) and 8-isoprostane,
CRP, total MMP-9, or its activity. Several previous studies
have demonstrated an association between serum CRP and
lung function parameters (FEV
1
(% predicted), FVC (%
predicted) or FEV
1
/FVC (%)) in asthma [14, 17, 18]. However,
the positive correlation between the ratio of FEV
1
/FVC
(%) and circulating 8-isoprostane is unexpected as weak
association being observed between sputum 8-isoprostane
and FEV
1
(% predicted) in a previous study [7]. Further
studies are needed to clarifywhether the relationship between
oxidative stress and airway obstruction exists in individual
patients.The negative correlation between plasma levels of 8-
isoprostane and total MMP-9 was consistent with previous
report showing that 8-isoprostane reducesMMP-9 activity in
vitro [33].
To the best of our knowledge, this is the first study to
assess the plasma levels of 8-isoprostane, CRP, and total
MMP-9 as well as MMP-9 activity in acute exacerbation
and in remission of the same patients. It has been suggested
that oxidative stress, inflammation, and airway remodeling
would be best studied in cells and fluids obtained from the
lungs such as induced sputum and BAL. We chose to study
plasma for several reasons. Blood is an easily available source
to study various biomarkers in asthmatic patients during
acute exacerbation and remission. BAL can provide direct
samples of airway cells, but the technique is invasive and
can only be performed in stable asthmatic patients. Despite
several confounding factors including aging and smoking,
whichmight affect plasma levels of CRP, age-matched healthy
controls for asthmatic patients were recruited, and smokers
were excluded from this study. One limitation of this inves-
tigation is that the sample size being studied is rather small.
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We nevertheless believe that these data are meaningful and
should prompt further large-scale investigations.
In conclusion, there is evidence of systemic oxidative
stress and systemic inflammation in asthma exacerbation,
which persists in remission. These findings suggest that
overproduction of MMP-9 along with oxidative stress and
inflammation is implicated in asthma exacerbation and that
measurements of these biomarkers (for oxidative stress,
inflammation, and remodeling) in blood can be a valid index
in the management of asthma to assess the status of oxidative
stress, inflammation, and remodeling.
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